Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation.
G-CSF
HSCT
cost-effectiveness
filgrastim
lenograstim
mobilization
Journal
Journal of blood medicine
ISSN: 1179-2736
Titre abrégé: J Blood Med
Pays: New Zealand
ID NLM: 101550884
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
07
2019
accepted:
09
03
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
21
4
2020
Statut:
epublish
Résumé
Granulocyte-colony stimulating factors (G-CSFs) are widely used to mobilize CD34 Between 2009 and 2016, 248 patients undergoing autologous HSCT have been evaluated and divided into three groups (100 Leno-Leno, 93 Leno-Fil, 55 Fil-Fil) according to the type of G-CSF used for hematopoietic stem cell mobilization and hematopoietic stem cell recovery after transplant. The following statistically significant differences have been observed between Leno-Leno, Leno-Fil, Fil-Fil groups: a higher number of harvested CD34 In our experience, Lenograstim outperforms Filgrastim in terms of effectiveness and lower cost. This study shows a clinical superiority of Lenograstim over Filgrastim suggesting a potential cost savings favoring Lenograstim.
Identifiants
pubmed: 32308515
doi: 10.2147/JBM.S224173
pii: 224173
pmc: PMC7135199
doi:
Types de publication
Journal Article
Langues
eng
Pagination
123-130Informations de copyright
© 2020 Restelli et al.
Déclaration de conflit d'intérêts
Dr Umberto Restelli reports grants from Italfarmaco, during the conduct of the study; personal fees from Italfarmaco, outside the submitted work. Dr Erminio Bonizzoni reports personal fees from Italfarmaco, during the conduct of the study. The authors report no other conflicts of interest in this work.
Références
Int J Clin Pharmacol Ther. 2011 Aug;49(8):510-8
pubmed: 21781651
Ann Hematol. 2017 Oct;96(10):1735-1739
pubmed: 28801752
J Blood Med. 2018 Dec 27;10:21-27
pubmed: 30643475
Leuk Res. 2011 Jul;35(7):899-903
pubmed: 21134693
Lancet. 1993 Feb 6;341(8841):369
pubmed: 7679177
Theranostics. 2014 Jan 23;4(3):280-9
pubmed: 24505236
Biologics. 2016 Jan 22;10:1-8
pubmed: 26858523
Ecancermedicalscience. 2013 Jun 25;7:327
pubmed: 23818939
Drugs. 2002;62(8):1207-13; discussion 1214-5
pubmed: 12010086
BioDrugs. 2017 Apr;31(2):117-124
pubmed: 28353170
Blood Rev. 2014 Jan;28(1):31-40
pubmed: 24476957
Target Oncol. 2012 Mar;7 Suppl 1:S29-34
pubmed: 22258705
Support Care Cancer. 2015 Nov;23(11):3131-40
pubmed: 25821144
Haematologica. 2011 Jul;96(7):942-7
pubmed: 21719883
Am J Med Sci. 1992 Jun;303(6):429-31
pubmed: 1376551
Clin Exp Med. 2015 May;15(2):145-50
pubmed: 24722996